Itroskin 200 Capsule contains Itraconazole 200 mg, a broad-spectrum triazole antifungal agent used for the treatment of various systemic and superficial fungal infections. Itraconazole exerts its antifungal effect by inhibiting the cytochrome P450-dependent enzyme lanosterol 14-α-demethylase, which is essential for the conversion of lanosterol to ergosterol, a critical component of fungal cell membranes. This disruption leads to increased membrane permeability and ultimately fungal cell death. Itroskin 200 is indicated for the management of infections such as aspergillosis, histoplasmosis, blastomycosis, onychomycosis, and candidiasis, including oropharyngeal and esophageal candidiasis. The capsule formulation ensures adequate bioavailability when taken with food, enhancing absorption. It is important to adhere to prescribed dosing regimens and complete the full course to prevent resistance and relapse. Caution is advised in patients with hepatic impairment or congestive heart failure, and potential drug interactions should be reviewed due to itraconazole’s inhibition of CYP3A4 enzymes. Common adverse effects include gastrointestinal disturbances, headache, and rash. Regular monitoring of liver function tests is recommended during prolonged therapy. Itroskin 200 should be used under medical supervision to ensure safety and therapeutic efficacy.